India’s Burmans Return To Trial Outsourcing With OneQuest
This article was originally published in PharmAsia News
Executive Summary
The Burman family, formerly of India's Dabur Pharma, is considering a return to the medical business with its privately held company, OneQuest. The firm plans to provide molecular diagnostics for the world's major drug-research and outsourced clinical-trial companies in all therapeutic areas. OneQuest has been focusing its business on test services for oncological clinical trials. Sources say OneQuest also plans eventually to conduct trials itself. The diagnostics business used to be a part of Dabur Pharma, but was transferred to OneQuest before Fresenius Kabi bought Dabur. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.